Structure Therapeutics (GPCR) Share-based Compensation (2022 - 2026)

Structure Therapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 96.67% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $34.7 million (up 612.19% YoY), while the FY2025 annual figure was $75.5 million, up 49.21% from the prior year.
• Share-based Compensation for Q1 2026 stood at $11.6 million, up from $8.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $11.6 million in Q1 2026, with the low at -$11.3 million in Q4 2024.
• The 5-year median for Share-based Compensation is $2.5 million (2023), against an average of $3.1 million.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 308.55% in 2023, then slumped 636.84% in 2024.
• Structure Therapeutics' Share-based Compensation stood at $623000.0 in 2022, then surged by 236.76% to $2.1 million in 2023, then plunged by 636.84% to -$11.3 million in 2024, then soared by 171.64% to $8.1 million in 2025, then jumped by 44.24% to $11.6 million in 2026.
• Business Quant data shows GPCR's Share-based Compensation at $11.6 million in Q1 2026, $8.1 million in Q4 2025, and $7.5 million in Q3 2025.